Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVAH NASDAQ:PSNL NYSE:TDOC NASDAQ:VRDN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVAHAveanna Healthcare$8.22+1.7%$5.59$3.67▼$8.41$1.72B2.031.43 million shs842,150 shsPSNLPersonalis$5.24+2.9%$5.65$2.83▼$7.79$464.67M1.76842,860 shs857,110 shsTDOCTeladoc Health$7.82+2.5%$7.78$6.35▼$15.21$1.38B1.844.89 million shs4.94 million shsVRDNViridian Therapeutics$18.72+0.4%$17.37$9.90▼$27.20$1.53B0.53850,923 shs799,775 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVAHAveanna Healthcare0.00%+2.75%+41.48%+49.18%+51.66%PSNLPersonalis0.00%+7.16%+15.16%+0.58%-2.78%TDOCTeladoc Health0.00%+1.05%+12.61%+7.43%+5.12%VRDNViridian Therapeutics0.00%+1.85%+13.25%+27.52%+26.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVAHAveanna Healthcare$8.22+1.7%$5.59$3.67▼$8.41$1.72B2.031.43 million shs842,150 shsPSNLPersonalis$5.24+2.9%$5.65$2.83▼$7.79$464.67M1.76842,860 shs857,110 shsTDOCTeladoc Health$7.82+2.5%$7.78$6.35▼$15.21$1.38B1.844.89 million shs4.94 million shsVRDNViridian Therapeutics$18.72+0.4%$17.37$9.90▼$27.20$1.53B0.53850,923 shs799,775 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVAHAveanna Healthcare0.00%+2.75%+41.48%+49.18%+51.66%PSNLPersonalis0.00%+7.16%+15.16%+0.58%-2.78%TDOCTeladoc Health0.00%+1.05%+12.61%+7.43%+5.12%VRDNViridian Therapeutics0.00%+1.85%+13.25%+27.52%+26.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVAHAveanna Healthcare 2.60Moderate Buy$7.50-8.76% DownsidePSNLPersonalis 3.00Buy$7.4241.54% UpsideTDOCTeladoc Health 2.35Hold$9.8025.26% UpsideVRDNViridian Therapeutics 2.90Moderate Buy$37.78101.80% UpsideCurrent Analyst Ratings BreakdownLatest PSNL, AVAH, VRDN, and TDOC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025VRDNViridian TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.008/19/2025AVAHAveanna HealthcareBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$5.50 ➝ $9.508/19/2025AVAHAveanna HealthcareUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell ➝ Neutral$6.75 ➝ $8.008/12/2025AVAHAveanna HealthcareUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$5.00 ➝ $6.758/11/2025AVAHAveanna HealthcareRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$9.008/7/2025VRDNViridian TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.008/7/2025VRDNViridian TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$45.00 ➝ $41.008/7/2025VRDNViridian TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$27.00 ➝ $26.008/7/2025VRDNViridian TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$28.00 ➝ $32.008/6/2025PSNLPersonalisBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.008/6/2025PSNLPersonalisHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.50(Data available from 9/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVAHAveanna Healthcare$2.02B0.85$0.16 per share50.13($0.64) per share-12.84PSNLPersonalis$84.61M5.49N/AN/A$2.87 per share1.83TDOCTeladoc Health$2.57B0.54$5.59 per share1.40$8.66 per share0.90VRDNViridian Therapeutics$300K5,095.58N/AN/A$6.09 per share3.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVAHAveanna Healthcare-$10.93M$0.08102.75∞N/A0.85%-54.56%3.17%11/6/2025 (Estimated)PSNLPersonalis-$81.28M-$1.28N/AN/AN/A-113.70%-47.57%-35.05%11/5/2025 (Estimated)TDOCTeladoc Health-$1.00B-$1.19N/AN/AN/A-8.16%-10.13%-4.43%10/29/2025 (Estimated)VRDNViridian Therapeutics-$269.95M-$3.83N/AN/AN/A-112,806.88%-78.95%-49.91%11/11/2025 (Estimated)Latest PSNL, AVAH, VRDN, and TDOC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025VRDNViridian Therapeutics-$1.00-$1.00N/A-$1.00$0.05 million$0.08 million8/5/2025Q2 2025PSNLPersonalis-$0.25-$0.23+$0.02-$0.23$20.12 million$17.20 million7/29/2025Q2 2025TDOCTeladoc Health-$0.27-$0.19+$0.08-$0.19$621.91 million$631.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVAHAveanna HealthcareN/AN/AN/AN/AN/APSNLPersonalisN/AN/AN/AN/AN/ATDOCTeladoc HealthN/AN/AN/AN/AN/AVRDNViridian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVAHAveanna HealthcareN/A1.091.09PSNLPersonalisN/A6.095.92TDOCTeladoc Health0.702.672.58VRDNViridian Therapeutics0.0411.0111.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVAHAveanna Healthcare87.96%PSNLPersonalis61.91%TDOCTeladoc Health76.82%VRDNViridian TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAVAHAveanna Healthcare7.00%PSNLPersonalis3.80%TDOCTeladoc Health0.58%VRDNViridian Therapeutics0.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVAHAveanna Healthcare33,500208.90 million194.27 millionOptionablePSNLPersonalis40088.68 million85.31 millionOptionableTDOCTeladoc Health5,500176.69 million175.67 millionOptionableVRDNViridian Therapeutics5081.66 million81.13 millionOptionablePSNL, AVAH, VRDN, and TDOC HeadlinesRecent News About These CompaniesInvesco Ltd. Has $644,000 Holdings in Viridian Therapeutics, Inc. $VRDNSeptember 7 at 3:03 AM | marketbeat.comViridian Therapeutics files automatic mixed securities shelfSeptember 6 at 6:36 AM | msn.comADAR1 Capital Management LLC Acquires 53,000 Shares of Viridian Therapeutics, Inc. $VRDNSeptember 4 at 7:41 AM | marketbeat.comPanagora Asset Management Inc. Increases Position in Viridian Therapeutics, Inc. $VRDNSeptember 4 at 5:23 AM | marketbeat.comRafferty Asset Management LLC Trims Position in Viridian Therapeutics, Inc. $VRDNSeptember 3, 2025 | marketbeat.comHsbc Holdings PLC Buys New Shares in Viridian Therapeutics, Inc. $VRDNSeptember 3, 2025 | marketbeat.comViridian Therapeutics, Inc. $VRDN Stake Lifted by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.comDriehaus Capital Management LLC Trims Stock Position in Viridian Therapeutics, Inc. $VRDNSeptember 1, 2025 | marketbeat.comWellington Management Group LLP Grows Position in Viridian Therapeutics, Inc. $VRDNSeptember 1, 2025 | marketbeat.comAnalysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $37.78August 31, 2025 | americanbankingnews.com248,628 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by Nuveen LLCAugust 30, 2025 | marketbeat.comAffinity Asset Advisors LLC Has $5.26 Million Stock Holdings in Viridian Therapeutics, Inc. $VRDNAugust 28, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 28, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Now Covered by Analysts at Jefferies Financial GroupAugust 27, 2025 | marketbeat.com13,742 Shares in Viridian Therapeutics, Inc. $VRDN Purchased by EntryPoint Capital LLCAugust 27, 2025 | marketbeat.comRussell Investments Group Ltd. Sells 181,338 Shares of Viridian Therapeutics, Inc. $VRDNAugust 27, 2025 | marketbeat.comAlgert Global LLC Sells 50,850 Shares of Viridian Therapeutics, Inc. $VRDNAugust 26, 2025 | marketbeat.comViridian Therapeutics, Inc. $VRDN Stake Cut by Vanguard Group Inc.August 26, 2025 | marketbeat.comViridian Therapeutics, Inc. $VRDN Shares Purchased by Candriam S.C.A.August 24, 2025 | marketbeat.comHC Wainwright Issues Optimistic Estimate for VRDN EarningsAugust 11, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Outlook for VRDN EarningsAugust 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSNL, AVAH, VRDN, and TDOC Company DescriptionsAveanna Healthcare NASDAQ:AVAH$8.22 +0.14 (+1.73%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$8.14 -0.08 (-0.96%) As of 09/5/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.Personalis NASDAQ:PSNL$5.24 +0.15 (+2.95%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$5.20 -0.04 (-0.76%) As of 09/5/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.Teladoc Health NYSE:TDOC$7.82 +0.19 (+2.50%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$7.82 -0.01 (-0.08%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Teladoc Health, Inc. provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems. The BetterHelp segment operates a mental health platform that provides online counseling and therapy services through website, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc, Livongo, and BetterHelp brands. It serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in Purchase, New York.Viridian Therapeutics NASDAQ:VRDN$18.72 +0.08 (+0.43%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$18.69 -0.03 (-0.16%) As of 09/5/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Union Pacific: Laying the Tracks for America's Industrial Renewal TransDigm’s Edge: From Spare Parts to Sky-High Profits Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
